This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Epigenetic Therapies And Technologies: World Market Prospects 2013-2023

8.2 Present and Future Epigenetic Research in Cancer

8.2.1 Twin Studies Reveal Epigenetic Biomarkers in Breast Cancer

8.2.2 Colorectal Cancer: Beyond Two Well-Established Biomarkers

8.2.3 Prognostic Markers in Lung Cancer

8.2.4 Prostate Cancer: Advances in Diagnostics, but Little Progress in Epigenetic Therapies

8.3 DNA Hypomethylation in Autoimmune Diseases

8.3.1 Lupus

8.3.2 Rheumatoid Arthritis as a Target for Drug and Diagnostic Development Case Study: Ignyta, Pioneering Epigenetic Diagnostics in Rheumatoid Arthritis

8.3.3 Diabetes Incidence is Linked to Ageing and Diet

8.4 Neurodegenerative Diseases

8.4.1 Alzheimer's Disease: Alleviation of Symptoms Using HDAC Inhibitors

8.4.2 Huntington's Disease: Epigenetic Drugs Approaching Clinical Development

8.5 Neurological Disorders

8.5.1 Drug Resistance in Schizophrenia

8.5.2 Autism is Linked to Many Genetic and Epigenetic Mutations

8.6 New Epigenetic Drug Targets

8.6.1 BET Proteins Are a Target in Many Therapeutic Areas

8.6.2 Assessing and Understanding DNA Hydroxymethylation

8.6.3 Sirtuins as an Underexploited HDAC Inhibitor Class

8.6.4 Histone Methyltransferase Lysine Methyltransferase Case Study: Domainex Developing HMT Inhibitors Protein Arginine Methyltransferases: Overcoming Insufficient Potency

8.6.5 Lysine Demethylases Show Promise as Targets for Cancer Therapies

9. Epigenetic Therapies and Technologies: Industry Trends 2013-2023

9.1 Epigenetic Therapies and Technologies Market: Strengths and Weaknesses 2011-20129.1.1 Understanding Epigenetic Markers and Mechanisms9.1.2 Specificity of Current Epigenetic Therapies9.2 Epigenetic Therapies and Technologies Market: Opportunities and Threats 2013-20239.2.1 The Importance of Translational Research9.2.2 Developing Companion Diagnostics9.2.3 Long Therapeutic and Diagnostic Pipelines9.2.4 Combination Therapy with Epigenetic Drugs9.2.5 Epigenetic Therapies to Overcome Drug Resistance9.2.6 Drug Targets Beyond HDAC and DNMT Inhibition9.3 Epigenetic Therapies and Technologies: STEP Analysis 2013-20239.4 Social Factors Influencing Product Development9.4.1 Epigenetics and the Environment9.4.2 Epigenetics, Ageing, and Disease9.4.2.1 Rising Global Disease Incidence to Drive Epigenetics Market Growth9.4.3 Targeting Orphan Indications and Patient Subpopulations9.4.4 Epigenetics Can Lead to Personalised and Stratified Medicine9.5 Technological Developments to Aid Epigenetic Research9.5.1 Next-Generation Sequencing Improving Epigenetic Research9.5.2 Using Epigenetics to Drive Forward Stem Cell Research9.5.3 Complementary and Competing Technologies9.5.3.1 Genomics9.5.3.2 Proteomics9.5.3.3 Metabolomics: A Comparatively New Discipline9.6 Economic Factors9.6.1 The Cost of Epigenetic Research9.6.2 The Role of Big Pharma in the Epigenetics Market 2013-20239.6.2.1 Pfizer9.6.2.2 Novartis: Performing Epigenetic Research in China9.6.2.3 GSK Has Signed Many Deals in Epigenetics9.6.3 Major Licensing Deals in Epigenetics9.6.4 Epigenetic Business Models9.7 Political Issues9.7.1 Ethics in Epigenetic Research9.7.2 Collaboration in Epigenetic Research9.7.2.1 Structural Genomics Consortium9.7.2.2 NIH Roadmap Epigenetics Project9.7.2.3 International Human Epigenome Consortium9.7.2.4 Blueprint: Contributing to Global Epigenome Libraries

7 of 12

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs